Newsfeeds - Spark Newswire

1 minute read

CytoSorbents Announces Filing Of Investigational Device Exemption For US Clinical Trial On Apixaban And Rivaroxaban Removal By DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

Today, 7:35 AM

CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption

CTSO

1 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 7:35 AM

ALKS

1 minute read

CytoSorbents, Aferetica Launch Organ Perfusion System In Italy

By Vandana Singh

Today, 7:35 AM

CytoSorbents Corporation (NASDAQ:CTSO) and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy’s European Society of Organ Transplantation Congress. Aferetica’s…

CTSO

1 minute read

Earnings

Looking into CytoSorbents’s Return on Capital Employed

By Benzinga Insights

Today, 7:35 AM

After pulling data from Benzinga Pro it seems like during Q2, CytoSorbents (NASDAQ:CTSO) brought in sales totaling $12.02 million. However, earnings decreased 72.66%, resulting in a loss of $4.92 million.

CTSO

1 minute read

CytoSorbents’ Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag

By Vandana Singh

Today, 7:35 AM

The FDA has granted a second Breakthrough Device designation to CytoSorbents Corporation’s (NASDAQ:CTSO) DrugSorb-ATR Antithrombotic Removal System. The designation covers removing the…

BMY

2 minute read

12 Health Care Stocks Moving In Thursday’s Pre-Market Session

By Benzinga Insights

Today, 7:35 AM

APRE

3 minute read

FDA
News

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents’ DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery

By Benzinga Newsdesk

Today, 7:35 AM

CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption

CTSO